Recent strategies to overcome the hyperacute rejection in pig to human xenotransplantation

Yale Journal of Biology and Medicine

Volumn 74, Issue 5, 2001, Pages 329-340

  Igaz, P ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ALPHA GALACTOSIDASE; ANTIIDIOTYPIC ANTIBODY; CD59 ANTIGEN; COBROTOXIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT RECEPTOR; CYCLOSPORIN A; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 3; MEMBRANE COFACTOR PROTEIN; OLIGOSACCHARIDE; REGULATOR PROTEIN; SOLUBLE COMPLEMENT RECEPTOR 1; STEM CELL FACTOR; UNCLASSIFIED DRUG;

CHIMERA; COMPLEMENT SYSTEM; DRUG EFFECT; GENE THERAPY; GENETIC TRANSFECTION; GRAFT REJECTION; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; INFECTION; NONHUMAN; PLASMAPHERESIS; SHORT SURVEY; SWINE; XENOTRANSPLANTATION;

ANIMALS; GRAFT REJECTION; HUMANS; SWINE; TISSUE DONORS; TRANSPLANTATION, HETEROLOGOUS;

SUS SCROFA;

EID: 0035657640     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (65)

1. Xenotransplantation
2. Xenotransplantation
3. Xenotransplantation
4. Xenotransplantation
5. Approaching the clinical application of xenotransplantation
6. Acute vascular rejection
7. Xenotransplantation: The importance of the Galα1,3Gal epitope in hyperacute vascular rejection
8. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: A major obstacle for xenotransplantation in humans
9. How many human B-cells are spontaneously producing antibodies against animal cells?
10. Anti-Galα1-3Gal antibody levels in organ transplant recipients receiving immunosuppressive therapy
11. The role of complement in transplantation
12. Complement activation, its consequences and blockade by gene transfer
13. The evaluation of thrombomodulin activity in porcine to human xenotransplantation
14. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors
15. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor
16. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates
17. Pancreatic islet xenotransplantation: The potential for tolerance induction
18. Xenogeneic islet transplantation
19. Interaction of baboon anti-α-galactosyl antibody with pig tissues
20. α-galactosyl epitopes on glyco-proteins of porcine renal extracellular matrix
21. Naturally occurring α-galactosyl antibodies in human sera display polyreactivity
22. Ig-therasorb immunoapheresis in orthotopic xenotransplantation of baboons with landrace pig hearts
23. Accommodation: A working paradigm for progressing toward clinical discordant xenografting
24. Long-term survival of hamster hearts in presensitized rats
25. Intravenous infusion of Gal α1-3Gal oligosaccharides in baboons delays hyperacute rejection of porcine xenografts
26. Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-alpha Gal antibodies
27. Cobra venom factor stimulates anti-alpha galactose antibody production in baboons: Implications for pig-to human xenotransplantation
28. Potentiation of C1 inhibitor plus heparin in prevention of complement mediated activation of endothelial cells in a model of xenograft hyperacute rejection
29. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts
30. Mixed chimerism as an approach to transplantation tolerance
31. Mixed chimerism and transplantation tolerance
32. Anti-Gal(α) 1-3Gal antibody response to porcine bone marrow in unmodified baboons and baboons conditioned for tolerance induction
33. Tolerization of anti-Galα1-3Gal natural antibody-forming B cells by induction of mixed chimerism
34. T cell and B cell tolerance to GALα1,3GAL-expres sing heart xenografts is achieved in α1,3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism
35. Long-term discordant xenogeneic (porcine-to-primate) bone marrow engraftment in a monkey treated with porcine-specific growth factors
36. Cross-species interaction of porcine and human integrins with their respective ligands: Implications for xenogeneic tolerance induction
37. Cross-species compatibility of intercellular adhesion molecule-1 (CD54) with its ligands
38. Inhibition of xenoreactive natural antibody production by retroviral gene therapy
39. Influence of cold ischemia time, pretransplant anti-porcine antibodies and donor/recipient size matching on hyperacute graft rejection after discordant porcine to cynomolgus kidney transplantation
40. Cloned pigs produced by nuclear transfer from adult somatic cells
41. Pig cloning by microinjection of fetal fibroblast nuclei
42. Changes in cell surface glycosylation in α1,3-galacto-syltransferase knockout and α1,2 fucosyl-transferase mice
43. Molecular cloning of endo-β-galactosidase C and its application in removing α-galactosyl xenoantigen from blood vessels in the pig kidney
44. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage
45. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs
46. Long-term survival of non-human primates receiving life-supporting transgenic porcine kidney xenografts
47. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation
48. Purification and characterization of the pig analogue of human membrane cofactor protein (CD46/MCP)
49. Complement-inhibiting activation of human CD59 and analogues from rat, sheep and pig are not homologously restricted
50. Molecular cloning and functional characterization of the pig analogue of CD59: Relevance to xenotransplantation
51. Structure/function characterization of porcine CD59
52. Resistance against the membrane attack complex of complement induced in porcine endothelial cells with a Galα(1-3)Gal binding lectin, up-regulation of CD59 expression
53. Xenotransplantation 2000
54. Xenosis and xenotransplantation: Addressing the infectious risks posed by an emerging technology
55. Endogenous retroviruses: A potential problem for xenotransplantation
56. Infection of human cells by an endogenous retrovirus of pigs
57. Binding of human natural antibodies to non α Gal xenoantigens on porcine erythrocytes
58. Binding of measles virus to membrane cofactor protein (CD46): Importance of disulphide bonds and N-glycans for the receptor function
59. Decay-accelerating factor (CD55), a glyco-sylphosphatidilinositol-anchored complement regulatory protein is a receptor for several echoviruses
60. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells
61. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry
62. The seven-organ transmembrane receptor CD97 has a cellular ligand (CD55, DAF)
63. CD59 molecule: A second ligand for CD2 in T cell activation
64. Molecular remodelling of human CD46 for xenotransplantation: Designing a potent complement regulator without measles virus receptor activity
65. The alpha-1,3-galactosyltransferase knockout mouse: Implications for xenotransplantation